Action BMEA BIOMEA FUSION, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Biomea Fusion, Inc.

Actions

BMEA

US09077A1060

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
5,6 USD +4,48 % Graphique intraday de Biomea Fusion, Inc. +19,15 % -61,43 %
11/06 BIOMEA FUSION, INC. : Truist Securities de acheteur à neutre sur le titre ZM
07/06 Mise à jour sectorielle : Les actions du secteur de la santé en hausse en fin d'après-midi MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
ROSEN, A LEADING LAW FIRM, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation - BMEA
NE
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
BMEA Investors Have Opportunity to Lead Biomea Fusion, Inc. Securities Fraud Lawsuit
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEA
BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
PR
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
GL
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
GL
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
AQ
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BMEA
  4. Actualités Biomea Fusion, Inc.
  5. Communiqués